Abstract:
:Mesenchymal stem cells (MSCs) show considerable promise as a cellular immunotherapy for the treatment of a number of autoimmune and inflammatory disorders. However, the precise physiologically and therapeutically relevant mechanism(s) by which MSCs mediate immune modulation remains elusive. Dental pulp stem cells are a readily available source of MSCs that have been reported to show similar immune modulation in vitro as bone marrow MSCs. To test their potential in vivo, we used a clinically relevant humanized mouse model of GvHD in which only human T cells engraft. In this model, we found no effects on either T-cell proliferation, T-cell phenotype or disease progression. To determine if this lack of efficacy was related to a failure of engraftment or persistence of the cells, we used viability dependent radioactive cell tracking and showed that no cells were detectable after 24-h postinjection. Given the apparent failure of MSC to survive following intravenous injection, we hypothesized that their apoptosis may account for the widely reported therapeutic effect in numerous experimental models in vivo. To address this, we employed a well-established model of allergic airway inflammation to compare the efficacy of live and apoptotic MSCs in a fully immunocompetent model. In this model, both live and apoptotic dental pulp MSCs induced a robust immune suppressive reaction that was substantially greater with apoptotic cells. We propose that the mechanism of immune modulation following systemic application of MSCs is a result of cell entrapment and apoptosis occurring in the lungs.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Laing AG,Riffo-Vasquez Y,Sharif-Paghaleh E,Lombardi G,Sharpe PTdoi
10.2217/imt-2017-0117subject
Has Abstractpub_date
2018-03-01 00:00:00pages
201-211issue
3eissn
1750-743Xissn
1750-7448journal_volume
10pub_type
杂志文章相关文献
Immunotherapy文献大全abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...
journal_title:Immunotherapy
pub_type: 面试,新闻
doi:10.2217/imt.13.27
更新日期:2013-05-01 00:00:00
abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.59
更新日期:2014-01-01 00:00:00
abstract::Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.154
更新日期:2012-01-01 00:00:00
abstract::Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.99
更新日期:2011-02-01 00:00:00
abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0048
更新日期:2017-11-01 00:00:00
abstract::Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0031
更新日期:2016-11-01 00:00:00
abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0105
更新日期:2019-02-01 00:00:00
abstract::Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.09.85
更新日期:2010-01-01 00:00:00
abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.68
更新日期:2013-08-01 00:00:00
abstract:AIM:This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE:To evaluate four maintenance doses of the allergoid preparation v...
journal_title:Immunotherapy
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/imt-2018-0087
更新日期:2018-09-01 00:00:00
abstract::Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.33
更新日期:2014-01-01 00:00:00
abstract::The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cel...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/1750743X.1.1.27
更新日期:2009-01-01 00:00:00
abstract::While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0153
更新日期:2019-02-01 00:00:00
abstract::The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.17
更新日期:2013-04-01 00:00:00
abstract::Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/1750743X.1.2.281
更新日期:2009-03-01 00:00:00
abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0188
更新日期:2021-01-01 00:00:00
abstract::Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0194
更新日期:2020-09-01 00:00:00
abstract::Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.1
更新日期:2015-01-01 00:00:00
abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.176
更新日期:2014-01-01 00:00:00
abstract::Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.101
更新日期:2016-01-01 00:00:00
abstract::Bacillus Calmette-Guérin and other mycobacterial vaccines are important therapeutic methods in a series of chronic inflammatory disorders characterized by Th1/Th2 imbalance in which Th2 type cells and cytokines often increase. However, few studies have investigated whether it can reduce or prevent the symptoms and att...
journal_title:Immunotherapy
pub_type: 杂志文章,随机对照试验
doi:10.2217/imt.12.156
更新日期:2013-02-01 00:00:00
abstract::Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC-IV) melanoma treated with anti-PD-1 in first-lin...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0217
更新日期:2021-03-01 00:00:00
abstract::Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.11.28
更新日期:2011-05-01 00:00:00
abstract::The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at cont...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.29
更新日期:2010-07-01 00:00:00
abstract::Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.13.155
更新日期:2014-01-01 00:00:00
abstract::TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.111
更新日期:2013-10-01 00:00:00
abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0266
更新日期:2021-02-01 00:00:00
abstract::Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/1750743X.1.2.187
更新日期:2009-03-01 00:00:00
abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0027
更新日期:2017-08-01 00:00:00
abstract::Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.61
更新日期:2014-01-01 00:00:00